These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16431045)

  • 1. Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis.
    Perkins AC; Frier M; Blackshaw PE; Spiller RC; Fairbairn KJ; Dansereau RJ; Kinghorn T; San P; Hosking D
    Int J Pharm; 2006 Mar; 311(1-2):20-5. PubMed ID: 16431045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
    Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
    Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.
    Perkins AC; Wilson CG; Frier M; Blackshaw PE; Juan D; Dansereau RJ; Hathaway S; Li Z; Long P; Spiller RC
    Aliment Pharmacol Ther; 2001 Jan; 15(1):115-21. PubMed ID: 11136284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water.
    Perkins AC; Wilson CG; Frier M; Blackshaw PE; Dansereau RJ; Vincent RM; Wenderoth D; Hathaway S; Li Z; Spiller RC
    Int J Pharm; 2001 Jul; 222(2):295-303. PubMed ID: 11427359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations.
    Perkins AC; Wilson CG; Frier M; Vincent RM; Blackshaw PE; Dansereau RJ; Juhlin KD; Bekker PJ; Spiller RC
    Int J Pharm; 1999 Sep; 186(2):169-75. PubMed ID: 10486435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
    Walker AD; Adachi JD
    Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers.
    Simanjuntak R; Setiawati E; Yunaidi DA; Handayani LR; Setiawati A; Utami BS; Rosa TA; Sholeh AB
    Drug Res (Stuttg); 2014 Mar; 64(3):136-40. PubMed ID: 24002927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive radionuclide esophagogastrointestinal transit study: methodology, reference values, and initial clinical experience.
    Antoniou AJ; Raja S; El-Khouli R; Mena E; Lodge MA; Wahl RL; Clarke JO; Pasricha P; Ziessman HA
    J Nucl Med; 2015 May; 56(5):721-7. PubMed ID: 25766893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; Rubí S; Oppenheimer F
    Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract.
    Stevens HN; Speakman M
    Curr Med Res Opin; 2006 Dec; 22(12):2323-8. PubMed ID: 17257446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
    Houghton LA; Atkinson W; Whorwell PJ; Morris J; Murdoch RD; Cooper SM; Webber DM; Walls CM
    Clin Ther; 2006 Apr; 28(4):569-81. PubMed ID: 16750468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
    Ilter E; Karalok H; Tufekci EC; Batur O
    Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monthly risedronate (Actonel) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2008 Sep; 50(1294):69-70. PubMed ID: 18772843
    [No Abstract]   [Full Text] [Related]  

  • 15. The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans.
    McCargar L; Crail D; Dansereau R; Myers W; Lane M
    Int J Pharm; 2001 Jul; 222(2):191-7. PubMed ID: 11427349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
    Bock O; Boerst H; Thomasius FE; Degner C; Stephan-Oelkers M; Valentine SM; Felsenberg D
    J Musculoskelet Neuronal Interact; 2007; 7(2):144-8. PubMed ID: 17627083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal osteoporosis patients.
    Fernandes CE; Zerbini C; Russo LA; Albernaz MA; Eis SR; Szejnfeld VL; Pompei LM
    J Clin Densitom; 2009; 12(1):77-83. PubMed ID: 19004654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extemporaneous procedures for dissolving risedronate tablets for oral administration and for feeding tubes.
    Dansereau RJ; Crail DJ
    Ann Pharmacother; 2005 Jan; 39(1):63-7. PubMed ID: 15590875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
    Racewicz AJ; Schofield PJ; Cahall DL; Cline GA; Burgio DE
    Curr Med Res Opin; 2007 Dec; 23(12):3079-89. PubMed ID: 17971285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.